Life Sciences Archive » October, 2012

Life Sciences - October, 2012

249 articles

• SigmaPharm Looks To Relaunch Skelaxin Antitrust Battle
• FDA Seems Unlikely To Move Hydrocodone To Stricter Class
• FDA Should Use Foreign Oversight For Food Imports, GAO Says
• Ex-Orthofix Sales Manager Pleads Guilty To Medicare Fraud
• Suspension Of Novartis Flu Vaccines Lifted In 2 Countries
• Pharmacy Recalls All Drugs Amid Meningitis Outbreak Probe
• FTC To OK Corning's $730M Labware Buy, With Conditions
• Stryker Again Seeks To Block Exec From Jumping To Zimmer
• Inspiration Biopharmaceuticals Files For Ch. 11, Seeks Buyer
• Look Before You Leap Into A Securities Litigation Trap
• Cephalon Faces Class Cert. Bid In Actiq Marketing Row
• Diet Supplement Maker SEI Dodges DMAA Class Action
• Muslim Woman's Vitamin Label Claims Preempted, Judge Says
• Biogen Challenges USPTO Patent Term Adjustment Policy
• Donut Hole Drug Prices Kept In Check By ACA, Report Says
• Stem Cell Co. Says Rival Infringed Blood Product Patents
• Peregrine Sued By Investors Over Cancer Drug Claims
• Nutraceutical Can't Shake 'Yummi Bears' Trademark Claims
• Novartis Inks $20M Deal To End Texas Medicaid Fraud Suit
• 7 Tips For Avoiding False Claims Act Whistleblower Suits
• 2 In Federal Zoloft MDL Want Case Kicked Back To Calif.
• Sullivan Steers Bayer's $1.2B Schiff Nutrition Buy
• Opportunities And Challenges Of Telemedicine
• NIH Should Open Patents For Abbott HIV Drug, Petition Says
• CAFA Provides Wide Removal Power, NAM Tells High Court
• Banana Boat Sunscreen Ads Are Misleading, Class Says
• Bar Association Asks Fed. Circ. To Clarify Role On Obviousness
• Caldera Fails To Escape J&J Pelvic Mesh MDL Claims
• Stryker Sues Zimmer, Ex-Employee Over Trade Secrets Breach
• NJ Judge Won't Reconsider Tossing Shareholder's Vioxx Suit
• Watson Sheds Rugby OTC Drug Line In $117M Deal
• Stanford, Prenatal Blood Test Co. Say Rival Infringes Patent
• New Zealand Warns Of Zimmer Hip Implants' Early Failure
• Dietary Supplement Marketers Now Under OIG Scrutiny
• BioTech Firm Says Heller Ehrman Patent Gaffe Cost It $100M
• Meningitis Outbreak Exposes Oversight Failures, Markey Says
• Canada Pulls Novartis Flu Vaccines Over Safety Concerns
• Omeros Can't Exclude NIH Testimony From Ex-CFO's FCA Suit
• J&J OK'd To Proceed With Investor Deal In Compliance Row
• Fed. Circ. Won't Review USPTO, Court Split On Validity
• FDA Finds Sanitation Lapses At Pharmacy Linked To Outbreak
• Novartis Given Reprieve In Elidel FCA Suit
• Gene Sequencer Says Ex-Partner's $138M Deal Broke Promises
• AmerisourceBergen, Pharmacy At Draw In $106M Contract Row
• Cincinnati Fights Coverage of W.Va. AG's 'Pill Mill' Suit
• FDA Halts Distribution At 2 Supplement Makers
• Evanston Seeks To Escape Coverage Of Fungal Dye Suits
• Teva, GSK Face Another Suit Over Generic Lamictal Deal
• Romney Could Give Health Cos. Raked By Probes Willing Ear
• GSK Targeted In Antitrust Suit Over Drug-Discount Program
• Forest Lab Settles Bystolic Patent Row With Generic Drugmaker
• In Support Of Learned Intermediary Doctrine
• Merck Can't Shield Testimony Docs In NuvaRing MDL
• St. Jude Escapes Volcano's Patent Claims Over Heart Device
• Pfizer Won't Face Retrial In Premarin Breast Cancer Suit
• St. Jude Investors Win Class Cert. In Stock Fraud Suit
• Pfizer, Ranbaxy Can't Pause Lipitor Pay-For-Delay Suit
• Boehringer Pays $95M To Settle FCA Suit Over Drug Marketing
• Glaser Weil Guides OpenGate's Purchase Of Thermo Fisher Unit
• Branded Drug Cos. Not Liable For Generics, 5th Circ. Rules
• Medtronic Manipulated Bone Device Studies, Report Says
• Bayer Can't Escape Employee's FCA Retaliation Suit
• Simpson Thacher Aids McKesson In $2.1B Medical Supplier Buy
• A Growing Problem For Multinational Pharmas
• Resistance May Be Pharmacy's Best Bet In Meningitis Probe
• PE Firm Wants Out Of Class Deal To Sue Celera Over Buyout
• Lawmakers Release New Drug Track-And-Trace Proposal
• Ore. Lands $4M Settlement In McKesson Drug Pricing Case
• NJ Courts Mull Centralized Stryker Hip Implant Litigation
• CORRECTED: DC Anti-SLAPP Law Preempted In 3M Blackmail Suit, Judge Says
• Pfizer, Bayer, J&J Push Phony Expiration Dates: Class Suits
• Insurer Asks Supreme Court To Stop 'End Run' Around CAFA
• Generic Pharmaceutical Liability: Challenges And Changes
• GSK, Teva Can't Put Brakes On Pay-For-Delay Challenge
• K-V Takes Fight Over Makena Knockoffs To ITC
• FDA Warns Alere Over Weak Response To Manufacturing Errors
• AstraZeneca Affiliate Running Factory Cleanup Enters Ch. 11
• Roche Faces Potential Fine In EU Safety Probe
• Wash. Judge Won't Stop Actos Generic For Mylan Appeal
• Antitrust Experts See 2 Front-Runners For Sen. Kohl's Post
• Wyeth Says 3rd Circ. Appeal Stays Philly Fen-Phen Trial
• Pharmacists Push Pa. Gov. To Sign Pharmacy Choice Bill
• House Expands Probe Into Deadly Meningitis Outbreak
• Bayer Calls False Ad Class Actions Over Probiotics Flimsy
• Medical Body Area Networks: Promising Yet Risky
• How To Get The Most Out Of Your Statistical Sampler
• Abbott, Other Stent Makers Seek Toss Of Off-Label FCA Suit
• U of Calif. Breached X-Ray Licensing Deal, Caldera Says
• K-V Pharma Reaches $7.5M Deal With Zydus Pharma
• Guidant Pushes US To Prove FCA Claims Aren't Resolved
• Purdue's OxyContin Patent Suit Survives Dismissal Bid
• Meningitis Probe Could Cause Drug Shortages, FDA Says
• Volcano Didn't Infringe St. Jude Device Patents, Jury Says
• CORRECTED: Gore Asks Justices To Review Joint Inventor Standard
• Judge Orders FDA To Approve Watson's Generic Actos
• In ADHD Play, Pfizer Inks $700M Deal For NextWave Pharma
• Liability Claims In Pa. Prevacid Suit Pared, Punitives Allowed
• Complying With HIPAA: A Blur For Health Tech Cos.
• Another Case Highlights Ambiguity Of Pharma Liability
• Legal Industry Trends: Lawyer Salaries And Job Growth
• Feds Can't Ignore Rulemaking Comments, Supreme Court Hears
• Hunton & Williams Hires Charlie Crist's Ex-GC In Miami
• Trade Secrets — Less Risky Under AIA Prior User Rights?
• Powerful House, Senate Panels Set For Election Year Shake-Up
• FDA Panel Recommends Approval Of Genzyme's Kynamro
• European Regulators Reject Vivus Obesity Drug Used In US
• Omnicare Whistleblower Can't Revive Tainted Drugs Claims
• Sen. Urges Crackdown On Misleading Power Wheelchair Ads
• OTC Drug Distributor Sues Contract Manufacturer Over Recalls
• Smith Gambrell Picks Up Ballard Spahr Technology Patent Pro
• In The FDA Crosshairs: Composite Scores In Drug Ads
• A View From Inside The Litigation Finance Market
• Meningitis Suits Stand To Benefit From FDA Criminal Probe
• Ferring, Aventis Trim Claims In DDAVP Antitrust Class Action
• Smith & Nephew Urges Fed. Circ. To Rethink Jury IP Findings
• US Slams Jailed Supplement Maker's Bid To Duck $450M Fine
• Pa. Judge To Rethink Delay In Wyeth Fen-Phen Trial
• The Cure For Calif.'s Food Suit Binge
• Pfizer Settles 1st Trial In Chantix Suicide MDL
• Cooley Closes 2nd Life Sciences Deal In 2 Days
• Ex-Sales Reps Challenge J&J Unit's Noncompete Deal
• Gene Sequencer's Investors Say $118M Deal Chilled Other Offers
• Medtronic Says Fed. Circ. Botched Burden-Of-Proof Analysis
• Pfizer Says Copay Subsidies Don't Harm Benefit Funds
• Illumina Patent Claims Invalidated In DNA Sequencing Row
• Vinson Scores Ex-Dickstein Shapiro Patent Pro In DC
• Franck's, FDA Seek To Drop Compounding Oversight Case
• Meningitis Victim's Widow Targets Drug Compounder
• Kelley Drye OK'd To Rep Ciba, Ex-Workers In Injury Row
• Arch Chemicals Faces Age-Bias Suit Over Post-Merger Layoffs
• Tricare Price Caps Unfair To Pharma Cos., DC Circ. Hears
• 4 Key Issues In Launching A Global Telemedicine Program
• Walgreen Says Insurer Owes It $3M For Avastin Defense
• Pfizer Fails To Delay Chantix Trial Despite New Study
• Give FDA More Data On Antibiotics In Livestock, Rep. Says
• OIG Urges Medicaid To Lower Drug Payment Limits Quickly
• FDA Questions Safety Of Genzyme's Kynamro
• Pharmacy Linked To Meningitis Outbreak Faces $15M Suit
• JPML Won't Centralize Gerber Baby Formula Suits
• 7th Circ. Lets Abbott Combine, Transfer Depakote Cases
• Ex-Purdue Execs Ask DC Circ. To Revisit HHS Ban Case
• UVA Whistleblower Nets Award In FCA Suit Over Health Grant
• Having One's Cake And Eating It Too In Post-Grant Review
• FDA Warns Avon Over Wrinkle-Product Marketing
• Sealing The Deal: Weil Races To Finish In $2.6B Medicis Sale
• Watson Gets FTC Nod For $5.5B Actavis Buy, With Concessions
• Obama, Romney Throw Blows Over Energy, Health Care, Trade
• Ear Candler Loses Cert. Bid In Suit Over FDA Warning Letters
• 2 More Drugs May Be Linked To Meningitis Outbreak, FDA Says
• CVS Pays $5M To End Whistleblower's Medicare Fraud Claims
• Extra Damages Bid In $22M Stent Suit Denied By Fed. Circ.
• Forest Targets Docs' Testimony In Lexapro, Celexa Suicide MDL
• Post-Meningitis Outbreak: Questioning FDA's Oversight
• Ranbaxy Wants In On Mylan's Suit Over Valsartan Exclusivity
• Allergan's Sanctura IP Appeal Turned Away By High Court
• Clifford Chance Guides Cinven's $589M Pharma Co. Buy
• Meningitis Plaintiffs Face Uphill Battle If Pharmacy Fails
• ITC To Probe Gnosis, Macoven's Folate Dietary Products
• House Meningitis Probe Sets Sights On State Pharmacy Board
• Questcor Execs Hid Athcor Woes To Pad Price, Suit Says
• Fed. Circ. Upholds $31M Win In Hearing Aid IP Suit
• AstraZeneca, Sandoz Dodge $30M Medicaid Fraud Verdicts
• Pfizer Asks 11th Circ. To Block CEO's Chantix MDL Testimony
• Meningitis Outbreak Spurs Push For Compounder Crackdown
• NIH Says Better Animal Studies Will Speed Drug Development
• Novartis Eye Drug Doesn't Infringe Rival's IP, UK Court Says
• Walgreen Fights Shipping Center's DEA Suspension At DC Circ.
• Womble Carlyle Snags Ex-Connolly Bove Patent Litigators
• GSK To Make Trial Data Available To Researchers
• Wyeth Loses Bid For Stay In Philly Fen-Phen Trial
• Fed. Circ. Denies Roche's Bid To Halt Boniva Generics
• Purdue Sues To Halt Sandoz's Generic OxyContin Plans
• Presidential Panel Calls For Gene Sequencing Privacy Rules
• 9th Circ. Targets Claims That Nidek Misused Lasik Beams
• Meningitis Outbreak Exposes FDA's Oversight Failures
• Fla. Hospital Wants Class Cert. In $867M Drug Antitrust Suit
• 1st Circ. Revives Fired Ex-Lax Plant Worker's Age Bias Suit
• Bausch & Lomb, Akorn Warned Over Unapproved Eye Drugs
• AAIPharma Gets Claims Slashed From Darvocet MDL
• Mylan Settles Dispute Over Generic Orapred ODT
• Sunshine Overseas: Transparency Rules For Life Sciences
• Merck Ordered To Turn Over Docs In Vioxx MDL
• K-Dur Applies To Authorized Generic Deals, FTC Insists
• Pharmacy Group Floats Plan To Save US $100B In Drug Costs
• Hill Seeks Probes, More Oversight After Drug-Caused Meningitis
• Dilworth Taps Ex-Saul Ewing Atty To Lead Health Care Practice
• Arnold & Porter Hires Pharma Industry Advocate In DC
• Pfizer Inks $164M Settlement In Celebrex Securities Suit
• Sanofi, Merck JV Recalls Faulty Typhoid Vaccine, UK Says
• Advice For Controlling Stockholder In 3rd-Party Merger
• Avanir Targets Impax Over Generic Nuedexta Plans
• FTC's Androgel Case May Not Be Best To Tackle Pay-For-Delay
• Druggists Say NY Medicaid Mail-Order Plan Harms Competition
• Saul Ewing Lures Patent, Biotech Atty From Cozen O'Connor
• Lawmakers Ask DEA For Clearer Policies On Pharmacy Supplies
• HMO Asks 1st Circ. To Uphold $142M Neurontin Verdict
• Pfizer Vows Appeal After India Revokes Sutent Patent
• Novartis Defeats Aredia-Zometa Suit Over Jaw Damage
• ANI, BioSante To Merge In $95M Stock Deal
• What The Supreme Court's Amgen Decision Will Mean
• EU OKs $5.2B Watson-Actavis Tie-Up
• 3 Ways To Make Your Next Deal Better, Faster, Cheaper
• Becton Dickinson Infringed 4 Hologic Patents, Judge Finds
• Deadly Outbreak Puts Compounded Drugs In FDA's Crosshairs
• Teva, Impax To Pull Generic Wellbutrin After FDA Finding
• FTC Takes Androgel Pay-For-Delay Case To High Court
• New Data Rescues Zymar Patent, Allergan Tells Fed. Circ.
• FTC Can't Weigh In On Effexor Authorized Generics Case
• J&J Resolves 5 Risperdal Off-Label Marketing Cases
• AngioDynamics Wins $16.5M Over Biolitec IP Indemnification
• FDA, Interpol Shut Down 18K Illegal Pharmacy Sites
• Case Study: In Re Pom Wonderful
• Reporting Under The Sunshine Act: Still In The Dark
• Apotex Says FDA Botched Plant Evaluation In Drug Approvals
• FDA Device Center Must Take Bigger Risks, Director Says
• HHS Report Gives A Leg Up To Supplement-Wary Lawmakers
• HHS Inspector General Plans New Reviews Of ACA Programs
• Generics Group Urges High Court To Take Pay-For-Delay Case
• Greenberg Traurig Brings Aboard King & Spalding Patent Atty
• Exxon, Lilly, Others Sued Over $21M In Superfund Costs
• Brown Rudnick's Bad Advice Led To $3M Penalty, SOI Says
• FTC 'Green Guides': What The Changes Mean For Marketers
• Sanofi Dismissal Affirmed In Generic Ambien Liability Suit
• US Blasts Cordis' Re-Exam Discovery Bid At Fed. Circ.
• Panel Sends Biomet Hip Implant MDL To Indiana
• Pfizer, King Can't Shake FCA Suit Over Medicaid Rebates
• Strengthening Medical Device Postmarket Surveillance
• ACA, Medicaid Mark Policy Contrast Between Obama, Romney
• Mylan Knocks Ranbaxy's Exclusivity Right For Valsartan
• FDCA Preempts Suit Over Medtronic Pacemaker Death: Judge
• Abbott Labs To Pay $700M In Depakote Criminal Case
• Merck Sues To Block Sandoz's Generic Zetia
• 6th Circ. Upholds Ohio Law Restricting Abortion Pill
• FDA Needs Certain Fundamental Reforms, Obama Adviser Says
• Zimmer Gets FDA Warning Letter Over Implant Manufacturing
• Is Obviousness The New Anticipation?
• FDA Wants Employee Email Spying Suit Dismissed
• Stakes Are High For Companies Negotiating CIAs
• Liberty Targets Drug Provider Over 'Pill Mill' Suit Coverage
• CORRECTED: FTC Pulls Antitrust Probe Over Yasmin Deals
• Medtronic Preemption Case Turned Away By Supreme Court
• $22M Award Won't Stop Cordis' Infringement, Fed. Circ. Told
• Grassley Presses Hospitals On Low-Cost Drug Program
• Roche's Boniva Patent Declared Invalid
• Sanofi Gets Reprieve In Amphastar's Lovenox FCA Suit
• High Court Won't Review Case Over Skelaxin Antitrust Standing
• Device Cos. Take Aim At Tax While Guarding FDA User Fees
• Trustee Urges High Court To Question CMS Payment Decisions
• China's Compulsory Licenses — A Danger To Pharma Patents